GlassScriptPhysician profile
Stacey B Schmidt
NPI 1205920493
$13,720.45
in general payments reported to CMS, 2019-2025
32 companies · $3,621 in 2025
The $3,621 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,432 · 2022: $2,345 · 2023: $2,043 · 2024: $3,279 · 2025: $3,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,612 · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,611.51 |
| Education | $331.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,636.73 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,979.75 | 2021-2025 | |
| Ucb, INC. | $1,183.35 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $951.66 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $918.72 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $753.09 | 2021-2025 | Blu-U, Odomzo, Ilumya |
| Lilly USA, LLC | $559.97 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $543.18 | 2022-2025 | Sotyktu |
| Incyte Corporation | $494.31 | 2021-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $464.65 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $452.79 | 2023-2025 | |
| Amgen INC. | $399.82 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $389.28 | 2021-2025 | Adbry, Anzupgo |
| Botanix Sb INC | $327.60 | 2025 | Sofdra |
| Pfizer INC. | $314.94 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $265.04 | 2021-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $198.02 | 2021-2022 | |
| Merz North America, INC. | $150.00 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $137.26 | 2021-2023 | Jublia, Arazlo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.78 | 2022-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Organogenesis INC. | $85.47 | 2024-2025 | Cygnus Dual, Novachor |
| Dermavant Sciences, INC. | $84.48 | 2023 | Vtama |
| Almirall LLC | $63.60 | 2021-2023 | Seysara |
| Helsinn Therapeutics (U.S.), INC. | $31.89 | 2022 | |
| Journey Medical Corporation | $26.57 | 2023 | |
| Biofrontera INC. | $22.43 | 2025 | Ameluz |
| Arcutis Biotherapeutics, INC. | $21.25 | 2023 | |
| Dermira, INC. | $20.68 | 2021 | |
| Verrica Pharmaceuticals INC. | $20.31 | 2023 | Ycanth |
| Vyne Pharmaceuticals INC. | $17.01 | 2021 | |
| Nabriva Therapeutics, Plc | $13.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.